4//SEC Filing
PERCEPTIVE ADVISORS LLC 4
Accession 0001062993-21-000859
CIK 0001454789other
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 7:15 PM ET
Size
16.0 KB
Accession
0001062993-21-000859
Insider Transaction Report
Form 4
PERCEPTIVE ADVISORS LLC
Director10% Owner
Transactions
- Award
Series X Convertible Preferred Stock
2021-02-01$3009.53/sh+4,851$14,599,230→ 4,851 total(indirect: See footnote)→ Common Stock (4,851,000 underlying) - Award
Series X Convertible Preferred Stock
2021-02-01$3009.53/sh+1,617$4,866,410→ 30,920 total(indirect: See footnote)→ Common Stock (1,617,000 underlying)
Xontogeny, LLC
Director10% Owner
Transactions
- Award
Series X Convertible Preferred Stock
2021-02-01$3009.53/sh+4,851$14,599,230→ 4,851 total(indirect: See footnote)→ Common Stock (4,851,000 underlying) - Award
Series X Convertible Preferred Stock
2021-02-01$3009.53/sh+1,617$4,866,410→ 30,920 total(indirect: See footnote)→ Common Stock (1,617,000 underlying)
Perceptive Xontogeny Venture Fund, LP
Director10% Owner
Transactions
- Award
Series X Convertible Preferred Stock
2021-02-01$3009.53/sh+4,851$14,599,230→ 4,851 total(indirect: See footnote)→ Common Stock (4,851,000 underlying) - Award
Series X Convertible Preferred Stock
2021-02-01$3009.53/sh+1,617$4,866,410→ 30,920 total(indirect: See footnote)→ Common Stock (1,617,000 underlying)
EDELMAN JOSEPH
Director10% Owner
Transactions
- Award
Series X Convertible Preferred Stock
2021-02-01$3009.53/sh+1,617$4,866,410→ 30,920 total(indirect: See footnote)→ Common Stock (1,617,000 underlying) - Award
Series X Convertible Preferred Stock
2021-02-01$3009.53/sh+4,851$14,599,230→ 4,851 total(indirect: See footnote)→ Common Stock (4,851,000 underlying)
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD
Director10% Owner
Transactions
- Award
Series X Convertible Preferred Stock
2021-02-01$3009.53/sh+4,851$14,599,230→ 4,851 total(indirect: See footnote)→ Common Stock (4,851,000 underlying) - Award
Series X Convertible Preferred Stock
2021-02-01$3009.53/sh+1,617$4,866,410→ 30,920 total(indirect: See footnote)→ Common Stock (1,617,000 underlying)
Footnotes (4)
- [F1]Upon stockholder approval of the conversion of Series X Convertible Preferred Stock into shares of common stock, each share of Series X Non-Voting Convertible Preferred Stock automatically converts into 1,000 shares of Common Stock, subject to certain limitations.
- [F2]The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- [F3]3. The securities are directly held by Perceptive Xontogeny Ventures, L.P. ("PXV"). The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- [F4]The securities reported herein were purchased from the Issuer pursuant to a Securities Purchase Agreement.
Issuer
CATABASIS PHARMACEUTICALS INC
CIK 0001454789
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001224962
Filing Metadata
- Form type
- 4
- Filed
- Feb 2, 7:00 PM ET
- Accepted
- Feb 3, 7:15 PM ET
- Size
- 16.0 KB